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Abstract (limited 250 words) 
 
Aims. The objectives of the present study were to determine the rates and associated factors of (i) 
MDD, (ii) antidepressant prescription and (iii) MDD non-remission in homeless subjects with 
bipolar disorder (BD) or schizophrenia (SZ). 
Methods. This multicenter study was conducted in 4 French cities. MDD was defined with the 
section L of the MINI. Unremitted MDD was defined by current antidepressant treatment and 
current MDD. 
Results. 700 subjects, mean aged 38 years and 82.5% men were included: 55.4% were diagnosed 
with MDD but only 10.4% were administered antidepressants. Violent victimization in the past 6 
months, alcohol use disorder and current substance abuse disorder were associated with 
increased rates of MDD. 71.2% antidepressant-treated subjects were unremitted. BD diagnosis 
and substance abuse disorder were found to be associated with increased risk of unremitted 
MDD. BD-MDD patients were found to be twice more frequently administered antidepressants 
than SZ-MDD ones, however the non-remission rates were higher in BD subjects compared to 
SZ. No antidepressant class and no specific antipsychotic or mood stabilizer has been associated 
with higher or lower rates of remitted MDD.  
Conclusion. MDD seems to be highly prevalent, underdiagnosed and undertreated in BD and SZ 
homeless subjects. Beyond antidepressants, add-on strategies including complementary agents, 
lithium, lamotrigine/carbamazepine or anti-inflammatory drugs and the specific care of alcohol 
and substance use disorders may be recommended to improve the prognosis of this specific 
population in addition to other interventions including housing and resocialization. Violent 
victimization is also frequent and should be specifically prevented in this vulnerable population. 
 
Keywords. Schizophrenia; Bipolar Disorders, Homelessness; major depression; antidepressant. 
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Introduction    
Treating Major Depressive Disorder (MDD) remains a therapeutic challenge in both 
schizophrenia (SZ) and bipolar disorders (BD). In schizophrenia, MDD is underdiagnozed, 
undertreated, with lower rates of remission under antidepressant treatments compared to non-SZ 
MDD subjects (Andrianarisoa et al., 2017; Guillaume Fond et al., 2018a). Bipolar depression 
remains a major challenge and a debate is ongoing to determine if antidepressant prescription 
should be recommended in bipolar depressed patients. A recent meta-analysis has concluded that 
reduced new depressive episodes may be achieved by long-term antidepressant treatment with no 
significantly increased risk of new manic/hypomanic episodes in BD(Liu et al., 2017). While SZ 
and BD remain highly prevalent in homeless people (Ayano et al., 2019; Welsh et al., 2012), little is 
known about MDD in this specific population, its prevalence and the effectiveness of 
psychotropic drugs. Additional factors including alcohol and substance use disorders that are 
highly prevalent in homeless subjects may also play a major role in depression diagnosis and 
remission under treatment(Lim et al., 2016).  
The objectives of the present study were to determine the MDD prevalence and 
associated factors in homeless subjects with BD and SZ, the rates of patients treated by 
antidepressants, the factors associated with antidepressant prescription, the rate of unremitted 
MDD patients under antidepressants and the factors associated with non-remission. 
 
Methodology 
 
Study design and population  
The French Housing First program was a multicenter randomized controlled trial 
conducted in 4 large French cities: Lille, Marseille, Paris and Toulouse (Tinland et al., 2013). 
The inclusion criteria were as follows: age over 18 years; absolute homelessness (i.e., no fixed 
place to stay for at least the past 7 nights with little likelihood of finding a place in the upcoming 
month) or precarious housing situation (housed in single-room occupancy, rooming house, or 
hotel/motel as a primary residence AND a history of 2 or more episodes of being absolutely 
homeless in the past year OR one episode of being absolutely homeless for at least 4 weeks in 
the past year); diagnosis of SZ or BD by a psychiatrist based on the Diagnostic and Statistical 
Manual of Mental Disorders, 4th ed. (DSM-IV-TR) criteria (American Psychiatric Association, 
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2000); and the ability to speak French. Mobile mental health outreach teams recruited patients 
from August 2011 to April 2014 in the street, emergency shelters, hospitals and jails. 
Psychiatrists and research assistants performed the evaluations during face-to-face interviews in 
the offices of the mobile mental health outreach teams, which were located in the downtown area 
of each city. The current analysis included only baseline data (t0, before any intervention). 
 
MDD, treated MDD and unremitted MDD definitions 
MDD was defined with the section L of the MINI (Sheehan et al., 1998). Treated MDD was 
defined by the administration of at least one antidepressant for more than 8 weeks at the time of 
evaluation. There is no consensual definition to date of remitted MDD in subjects with severe 
mental disorders to date. As the present study was an ecological/observational study, non-
remitted MDD was proxy by current antidepressant treatment for at least 8 weeks at the time of 
the evaluation(Guillaume Fond et al., 2018b). 
 
Data collection  
The following data were collected: 
- Sociodemographic information: gender, age.  
- Illness characteristics: Diagnoses (SZ, BD, alcohol use disorder, substance use disorder) 
were assessed with section L of the MINI(Sheehan et al., 1998).  
- Drug information: drug classes (antipsychotic, mood stabilizers, antidepressant) were 
reported. A specific group including olanzapine, quetiapine and aripiprazole (the three 
antipsychotics approved for the treatment of bipolar depression) has been analyzed to determine 
if these prescriptions were associated with lower depression rates and higher remission rates 
under antidepressants in BD subjects. 
 
Statistical analysis 
All variables are presented using measures of means and dispersion (standard deviation) 
for continuous data and frequency distribution for categorical variables. The data was examined 
for normal distribution with the Shapiro-Wilk test and for homogeneity of variance with the 
Levene test. Comparisons of demographic, clinical and treatment characteristics between MDD 
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and non-MDD patients (Table 1), treated and untreated (Table 2) and remitted MDD and 
unremitted MDD (Table 3) were performed using the chi-square test for categorical variables 
and Student t-tests or Mann-Whitney for continuous variables.  
Three multivariate logistic regressions were performed to determine which demographic, 
clinical and treatment characteristics were associated with MDD, antidepressant prescription and 
non-remission. The variables relevant to the models were selected from the univariate analysis, 
based on a threshold P-value ≤0.20. Two additional variables were included in the models 
because of its sociodemographic interest (age and gender). The final models incorporated the the 
adjusted Odds Ratios (aOR) and their corresponding 95% confidence interval (CI). 
All of the tests were two-sided. Statistical significance was defined as p < 0.05. Statistical 
analysis was performed using the SPSS version 20.0 software package (SPSS Inc., Chicago, IL, 
USA).  
 
Ethical approval 
The study was conducted in accordance with the principles of the Declaration of 
Helsinki, 6th revision. All participants provided written consent. The local ethics committee 
(Comité de Protection des Personnes Sud-Méditerranée V, France: trial number 11.050) and the 
French Drug and Device Regulation Agency (trial number 2011-A00668-33) approved the study.  
 
 
Results 
Overall, 700 HSB patients, mean aged 38 years and 82.5% men were included (479 
(68.9%) SZ and 216(31.1%) BD, 5 missing diagnoses). Current MDD was diagnosed in 388 
(55.4%) of the subjects (138/216 (63.8%) for BD vs. 246/479 (51.3%) for SZ) while only 73 
(10.4%) patients were treated by antidepressants. 420 (62.5%) reported a history of violent 
victimization in the past 6 months. BD patients with MDD were found to be twice more 
frequently administered antidepressants than SZ patients with MDD (39/145 (26.8%) for BD vs. 
34/260 (13.1%) for SZ).  
Compared to patients without MDD, MDD patients were found to have been more 
frequently victim of violence in the past 6 months (aOR=1.58[1.13-2.20], p=0.01), current 
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alcohol use disorder (aOR=1.41[1.01-1.97], p=0.04), current substance abuse disorder 
(aOR=2.27[1.63-3.18], p<0.0001) (Table 1, univariate and multivariate analyses). 
Compared to untreated MDD patients, patients being administered antidepressants were 
found to be slightly older (41.4 years vs. 38.7 years, aOR =1.03[1.01-1.06], p=0.04), to be more 
frequently bipolar (aOR=2.42[1.33-4.41], p=0.003), to have been more frequently victim of 
violence in the past 6 months (aOR=2.33[1.24-4.35], p=0.01) to have more frequently substance 
use disorders (aOR=1.83[1.02-3.30], p=0.04) (Table 2, univariate and multivariate analyses). 
Antidepressant treatment was not associated with increased current manic shift (38(13.4%) for 
patients without antidepressants vs. 13(18.8%) for those taking antidepressants, p=0.24), but 
were associated with a history of manic shift (36(13.1%) for patients without antidepressants vs. 
18(27.7%) for patients with antidepressants, p=0.004) (data not shown). 
Overall, 52 (71.2%) antidepressant-treated subjects were still diagnosed with MDD 
(=”unremitted MDD”) (32/39 (82.0%) for BD vs. 20/34 (58.8%) for SZ). BD subjects 
(aOR=3.13[1.01-9.76], p=0.04) and patients with substance abuse disorder (aOR=3.92[1.23-
12.47], p=0.02) were found to be at increased risk of unremitted MDD compared to remitted 
patients (Table 3, univariate and multivariate analyses).  
No antidepressant class (SSRI, NSRI) and no antipsychotic has been associated with 
higher or lower rates of remitted MDD (all p>0.05, data not shown). None of the participants 
treated by antidepressants was treated with clozapine, lithium, lamotrigine or carbamazepine, 
dietary complementary agents or anti-inflammatory drugs. 
 
Discussion 
The results of the present study may be summarized as follows: in a large multicentric 
sample of HSB subjects mean aged 38 years and 82% men, more than half was diagnosed with 
current major depressive disorder, while only 10% were treated by antidepressants and more than 
70% of those treated remained with major depression at the time of the evaluation. History of 
violent victimization, alcohol and substance use disorder were found to be associated with 
increased MDD. Bipolar patients and those with history of violent victimization and substance 
use disorder were more frequently prescribed antidepressants, and among them bipolar patients 
and those with substance use disorder were more frequently unremitted under treatment.  
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Major depression has been found to be highly prevalent both in BD (64%) and SZ (51%) 
subjects, while BD subjects were twice more frequently prescribed antidepressants (27% vs. 
13%). This result was not expected, as antidepressant prescription benefit/risk ratio has been 
extensively debated in bipolar depression(Baldessarini et al., 2018). Treatments have limited 
effectiveness and a debate is ongoing to determine if BD patients with MDD should be treated by 
antidepressants or not, some authors arguing that antidepressants may do more harm than good 
by increasing rapid cycling and manic shifts. Antidepressants have been found to be associated 
with past history of manic shift but not with current mania in our sample, which is in favor of a 
recommendation of careful prescription of antidepressants in patients at risk of manic shift (and 
especially aggressive manic shift). This risk may explain the very low rate of antidepressant 
prescription in our sample. 
Bipolar depression remains a major challenge for both housed and unhoused BD patients. 
Mood stabilizers and antipsychotics (olanzapine, aripiprazole, low-doses quetiapine) are 
currently recommended as treatments of reference in bipolar depression. However, neither 
valproate, olanzapine, aripiprazole or quetiapine have been associated with higher rates of 
remitted MDD in the present sample, and lithium, carbamazepine, lamotrigine and clozapine 
were not administered in the present sample of patients with unremitted MDD. It is therefore not 
possible to conclude from the present results that mood stabilizers are not effective in major 
depression in SZ and BD homeless subjects. However, there is a clear underprescription of these 
drugs in this population that may result from doctor and patient factors. From the doctor’s point 
of view, lithium may be associated with lethal risk in case of overdose, carbamazepine is 
associated the pharmacokinetic drug interactions and lamotrigine may be associated with acute 
immune-allergic cutaneous rash with potential lethal risk. All these prescription limits may 
induce a prescription bias. From the patient point of view, adherence into treatment may be 
better for drugs with an immediate effect (i.e., the drugs helping escaping reality rather than 
coping with it, including anxiolytic and hypnotic drugs (G. Fond et al., 2018c)). 
One may have expected that SZ subjects would be more likely to be administered 
antidepressants, given that antidepressants have shown effectiveness in SZ patients(Guillaume 
Fond et al., 2018b) and that the risk of manic shift is lower in schizophrenia compared to bipolar 
disorders. On the contrary, SZ patients were administered lower rates of antidepressants despite 
more than a half being diagnosed with major depression. This phenomenon is not limited to 
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homeless subjects and has been previously found in housed stabilized SZ subjects (Guillaume 
Fond et al., 2018b). Depression may be confounded with negative symptoms of schizophrenia 
(including blunted affect, anhedonia and lack of motivation). Treating psychiatrists may also be 
afraid of psychotic activation under antidepressants or drug interactions (through cytochrome 
modulation), however there is no supportive evidence for a psychotic activation under 
antidepressants and most of second-generation antidepressants have no interaction with 
antipsychotic drugs. The present results suggest that clinicians treating homeless subjects should 
always explore major depression in SZ subjects, by targeting specific mood symptoms including 
sadness, early awakening and suicidal ideation for example.   
It should be underlined that the remission rates are much lower than in non-homeless BD 
and SZ populations. In the present sample, 59% of the SZ subjects were still diagnosed with 
MDD despite an antidepressant treatment, vs. 44% of the housed SZ subjects of a previous 
French study (Guillaume Fond et al., 2018b). Several factors may explain this discrepancy, 
including age (the present sample was 6 years older on average than the previous study) and 
comorbidities (substance use disorder being more frequent in homeless subjects and having been 
associated with non-remission in the present sample). Another explanation may be due to higher 
rates of nutritional deficiencies in homeless subjects. No patient was found to be administered 
complementary agents, while omegas 3, vitamin D and methylfolate have shown effectiveness in 
the treatment of MDD in the general population in recent high-quality meta-analyses (Sarris et 
al., 2016; Schefft et al., 2017). Given that homeless subjects are at high risk of poor-quality food 
intake, this strategy should be specifically tested due to its high benefit/risk ratio. While 
homeless subjects may be at increased risk of chronic inflammation and while chronic peripheral 
inflammation has been associated with resistance to treatment in severe mental disorders(G. 
Fond et al., 2018b), none of the patients was administered anti-inflammatory drugs. These drugs 
should be also evaluated as a potentially useful treatment strategy in homeless subjects with 
severe mental disorders. Vitamin D supplementation has also shown effectiveness in housed 
patients with severe mental disorders and should be evaluated in homeless ones (G. Fond et al., 
2018a).  
These strategies should be combined with social interventions including housing 
programs for housing stability and family interventions for substance use outcomes (Wang et al., 
2019). Community engagement to build a collaborative approach to implementing depression 
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quality improvement across diverse programs has shown to be more effective than resources for 
services for individual programs in improving mental HRQL, physical activity and homelessness 
risk factors (Wells et al., 2013).Promoting mobile phone technologies could also improve other 
outcomes in this population (Raven et al., 2018).  
Patients with alcohol use disorder and substance use disorder were found to have higher 
rates of MDD and antidepressant prescription. These results suggest that addiction is not a 
motive for underprescription of antidepressants in our sample, while the debate to prescribe 
antidepressants in subjects with alcohol use disorder before or after alcohol withdrawal is still 
open(Foulds et al., 2015). Our results suggest that alcohol use disorder was not associated with 
increased non remission rates, it seems therefore reasonable to recommend the prescription of 
antidepressants in homeless subjects with BD/SZ and alcohol use disorder. This preliminary 
result should be confirmed by clinical trials. Further studies should also determine the reasons 
why substance use disorder has been associated with increased rates of non-remission under 
antidepressants in our sample. Several hypotheses may be suggested. First, these patients may 
have more adherence issues that have been extensively described elsewhere(Paudyal et al., 2017; 
Zemmour et al., 2016). Second, antidepressants may have lower intrinsic efficacy in this 
population due to differences in neuronal pathways activation, according to the substance intake. 
Managed alcohol programs and other alcohol-targeted interventions should be developed in 
homeless subjects with severe mental disorders(Pauly et al., 2019) as well as Mindfulness-
Oriented Recovery Enhancement that has shown effectiveness in Co-Occurring Substance 
Dependence, Traumatic Stress, and Psychiatric Disorders(Garland et al., 2016). 
Subjects reporting history of violent victimization were found to be at increased risk of 
MDD in the present study. This result is consistent with previous findings (Mackelprang et al., 
2014; Satyanarayana et al., 2015; Tong et al., 2019; Wong et al., 2016) and suggest that violent 
victimization should be prevented in this vulnerable population. Individuals with lived 
experience of homelessness face considerable marginalization, dehumanization and structural 
violence. It has been shown that re-entering housing may decrease the risk of victimization 
(Tong et al., 2019). While some intimate partner violence survivors require extensive and 
possibly long-term assistance to achieve safe and stable housing (especially if they are 
contending with multiple complex issues), others could avoid homelessness if provided with 
immediate, individualized, and flexible assistance(Sullivan et al., 2019). Practitioners and social 
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service providers should also consider anti-oppressive approaches and provide, refer to, or 
advocate for health and structural interventions using the principles of trauma-informed 
care(Magwood et al., 2019).  
Limits and perspectives. Some limits of the French Housing First trial have been 
previously described(G. Fond et al., 2018c). Because our study occurred in large cities, our 
findings may not be generalizable to homeless people living in smaller cities, where the life 
conditions and needs may differ. However, our study included southern and northern cities, thus 
taking into consideration socioeconomic, cultural and climatic differences. Persecutory delusion 
has been recently identified as a risk factor for non-remission in depressed SZ housed subjects 
(Guillaume Fond et al., 2018b) and has not been reported in the present study, as well as 
education level. Psychotic symptomatology should be more precisely investigated in future 
studies assessing major depression in homeless subjects. Daily tobacco smoking has been 
associated with MDD in the general population and has not been reported in the present study 
(Rey et al., 2017). History of rapid cycling has not been explored in BD patients due to memory 
bias issues. The absence of history of treatment data made us unable to define and explore 
resistance into treatment. Future studies should also include lifestyle evaluations (including diet, 
physical activity and sleep). The absence of biological data is another limit. Metabolic and 
inflammatory data and nutritional status may have been useful to explain the rates of MDD and 
recommend strategies (such as anti-inflammatory strategies or nutritional strategies for example). 
Yet obtaining biological data is more difficult in homeless patients than in non-homeless due to 
organizational and individual factors. The limit for lithium prescription may be due to 
dehydration risk in homeless subjects that has not been explored. The sample size for the last 
analysis was low, which may have limited the statistical power. 
Strengths. The strengths of the French Housing First trial have been previously 
described(G. Fond et al., 2018c), including the large sample size, the standardized evaluation, the 
detailed treatments and the lack of previous data on prescriptions behavior in homeless patients 
with severe mental disorders. 
 
Conclusion 
More than half of homeless subjects with severe mental disorders are diagnosed with 
major depression while only 10% being treated by antidepressants. In the light of the present 
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results, the following strategies (not exhaustively) should be further tested to improve MDD 
treatment in homeless subjects with severe mental disorders: complementary agents 
administration (including omega 3, vitamin D, methylfolate), lithium, carbamazepine and 
lamotrigine onset, anti-inflammatory drugs add-on therapy as indicated combined with the 
specific care of alcohol and psychoactive substance use disorders in addition to social 
interventions including housing programs, community engagement, early flexible funding, 
mobile phone and family interventions. Violent victimization is also frequent and should be 
specifically prevented in this vulnerable population. 
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